Office of the National Coordinator; American Health Information Community Chronic Care Workgroup Meeting, 24717-24718 [06-3918]

Download as PDF Federal Register / Vol. 71, No. 80 / Wednesday, April 26, 2006 / Notices wwhite on PROD1PC61 with NOTICES transition period, the Consent Agreement requires Abbott and Boston Scientific to enter into interim transitional service and confidentiality agreements. Finally, Abbott has taken a small equity position (under 5 percent) in Boston Scientific as part of the financing of Boston Scientific’s acquisition of Guidant. To limit any long-term entanglements between the parties, the proposed Consent Agreement requires Abbott to relinquish its voting rights (by voting its shares in the same proportion as all other shareholders in shareholder votes) and to divest its equity stake in Boston Scientific within thirty months of closing. Implantable Cardioverter Defibrillators ICDs are small electronic devices installed inside the chest to prevent sudden death from cardiac arrest due to abnormal heart rhythms. They are designed to counteract fibrillation of the heart muscle and restore normal heart rhythms by applying a brief electric shock. Three firms—Medtronic, Guidant, and St. Jude Medical—account for more than 98 percent of the $1.8 billion in annual sales in the U.S. ICD market, and have been the only competitively significant providers of ICDs in the United States for over ten years. Although Boston Scientific does not currently sell and is not developing any ICD products, it owns a ten to fifteen percent equity stake in a CRM start-up known as Cameron Healthcare Inc. More importantly, it has an option to acquire Cameron that provides certain information sharing and control rights prior to the exercise of the option. Cameron is developing a novel, ‘‘leadless’’ subcutaneous ICD that is on track to receive FDA approval in approximately two to three years. As in the DES, PTCA balloon catheter, and coronary guidewire markets, additional entry into the U.S. market for ICDs is difficult, time-consuming, and expensive. FDA approval is required to market ICDs in the United States and a new entrant would need to navigate around the substantial intellectual property barriers that exist in order to make a significant market impact. Boston Scientific’s option to acquire Cameron provides Boston Scientific with access to non-public information about Cameron and control over certain actions of Cameron that were originally intended to protect Boston Scientific’s investment. After Boston Scientific is combined with Guidant, those previously unobjectionable provisions may adversely affect competition in the ICD market because they allow the combined Boston Scientific/Guidant to VerDate Aug<31>2005 16:58 Apr 25, 2006 Jkt 208001 receive information from and exercise control over Cameron—a potentially significant future competitor. To alleviate these competitive concerns, the proposed Consent Agreement imposes limits on Boston Scientific’s access to Cameron information and on Boston Scientific’s ability to exercise any control over Cameron. First, a firewall will be established that will limit the circumstances under which Boston Scientific will receive Cameron information, as well as the individuals at Boston Scientific who may receive such information. Second, with respect to the control provisions, Boston Scientific will relinquish its right to exercise those provisions unilaterally. Pursuant to the proposed consent order, a proxy will be appointed who will independently determine whether Boston Scientific may exercise its contractual control rights. The purpose of the proxy is to ensure that Boston Scientific makes decisions with respect to the control provisions in the same manner as it would have absent the Guidant transaction. In making that determination, the proxy will act as an ordinary, prudent corporation of the scope of Boston Scientific (prior to the acquisition of the Guidant CRM business). Finally, with respect to the ten to fifteen percent equity stake held by Boston Scientific in Cameron, Boston Scientific has agreed to provisions similar to those governing Abbott’s equity investment in Boston Scientific, namely that it will vote its shares in the same proportion as all other shareholders in any shareholder vote. Furthermore, Boston Scientific will divest its equity investment in Cameron within eighteen months if it does not acquire control of Cameron prior to the expiration of its option or if it is enjoined from acquiring Cameron. To ensure that the Commission will have an opportunity to review any attempt by Boston Scientific to exercise its option to acquire Cameron, the proposed Consent Order contains a prior notice provision committing Boston Scientific to an H–S–R framework even if the transaction otherwise would be non-reportable. Appointment of an Interim Monitor and a Divestiture Trustee The proposed Consent Agreement contains a provision that allows the Commission to appoint an interim monitor to oversee Boston Scientific’s compliance with all of its obligations and performance of its responsibilities pursuant to the Commission’s Decision and Order. The interim monitor is PO 00000 Frm 00081 Fmt 4703 Sfmt 4703 24717 required to file periodic reports with the Commission to ensure that the Commission remains informed about the status of the divestitures, about the efforts being made to accomplish the divestitures, and the provision of services and assistance during the transition period for the divestiture. Finally, the proposed Consent Agreement contains provisions that allow the Commission to appoint a divestiture trustee if any or all of the above remedies are not accomplished within the time frames established by the Consent Agreement. The divestiture trustee may be appointed to accomplish any and all of the remedies required by the proposed Consent Agreement that have not yet been fulfilled upon expiration of the time period allotted for each one. The purpose of this analysis is to facilitate public comment on the proposed Consent Agreement, and it is not intended to constitute an official interpretation of the proposed Decision and Order or to modify its terms in any way. By direction of the Commission, with Commissioner Harbour recused. Donald S. Clark, Secretary. [FR Doc. E6–6226 Filed 4–25–06; 8:45 am] BILLING CODE 6750–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the National Coordinator; American Health Information Community Chronic Care Workgroup Meeting ACTION: Announcement of meeting. SUMMARY: This notice announces the fifth meeting of the American Health Information Community Chronic Care Workgroup in accordance with the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App.). DATES: May 3, 2006 from 1 p.m. to 5 p.m. Mary C. Switzer Building (330 C Street, SW., Washington, DC 20201), Conference Room 4090. ADDRESSES: FOR FURTHER INFORMATION CONTACT: https://www.hhs.gov/healthit/ahic/ cc_main.html. The meeting will be available via Web cast at https://www.eventcenterlive.com/ cfmx/ec/login/login1.cfm?BID=67. SUPPLEMENTARY INFORMATION: E:\FR\FM\26APN1.SGM 26APN1 24718 Federal Register / Vol. 71, No. 80 / Wednesday, April 26, 2006 / Notices Dated: April 13, 2006. Kelly Cronin, Director, Office of Programs and Coordination, Office of the National Coordinator. [FR Doc. 06–3918 Filed 4–25–06; 8:45 am] FOR FURTHER INFORMATION CONTACT: https://www.hhs.gov/healthit/ahic/ bio_main.html. The meeting will be available via Web cast at https://www.eventcenterlive.com/ cfmx/ec/login/login1.cfm?BID=67. SUPPLEMENTARY INFORMATION: BILLING CODE 4150–24–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the National Coordinator, American Health Information Community Electronic Health Records Workgroup Meeting ACTION: Announcement of meeting. SUMMARY: This notice announces the fifth meeting of the American Health Information Community Electronic Health Records Workgroup in accordance with the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App.). DATES: May 2, 2006 from 1 p.m. to 5 p.m. Dated: April 13, 2006. Kelly Cronin, Director, Office of Programs and Coordination, Office of the National Coordinator. [FR Doc. 06–3920 Filed 4–25–06; 8:45 am] BILLING CODE 4150–24–M DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the National Coordinator; American Health Information Community Consumer Empowerment Workgroup Meeting ACTION: Announcement of meeting. Mary C. Switzer Building (330 C Street, SW., Washington, DC 20201), Conference Room 4090. FOR FURTHER INFORMATION CONTACT: https://www.hhs.gov/healthit/ahic/ ehr_main.html. The meeting will be available via Web cast at https://www.eventcenterlive.com/ cfmx/ec/login/login1.cfm?BID=67. SUMMARY: This notice announces the fifth meeting of the American Health Information Community Consumer Empowerment Workgroup in accordance with the Federal Advisory Committee Act (Pub. L. No. 92–463, 5 U.S.C., App.) DATES: May 1, 2006 from 1 p.m. to 5 p.m. ADDRESSES: ADDRESSES: SUPPLEMENTARY INFORMATION: Dated: April 13, 2006. Kelly Cronin, Director, Office of Programs and Coordination, Office of the National Coordinator. [FR Doc. 06–3919 Filed 4–25–06; 8:45 am] BILLING CODE 4150–24–M Dated: April 13, 2006. Kelly Cronin, Director, Office of Programs and Coordination, Office of the National Coordinator. [FR Doc. 06–3921 Filed 4–25–06; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the National Coordinator; American Health Information Community Biosurveillance Workgroup Meeting wwhite on PROD1PC61 with NOTICES ACTION: BILLING CODE 4150–24–M Announcement of meeting. SUMMARY: This notice announces the fifth of the American Health Information Community Biosurveillance Workgroup in accordance with the Federal Advisory Committee Act (Pub. L. 92– 463, 5 U.S.C., App.). DATES: May 4, 2006 from 1 p.m. to 5 p.m. Mary C. Switzer Building (330 C Street, SW., Washington, DC 20201), Conference Room 4090. ADDRESSES: VerDate Aug<31>2005 16:58 Apr 25, 2006 Jkt 208001 Mary C. Switzer Building (330 C Street, SW., Washington, DC 20201), Conference Room 4090. FOR FURTHER INFORMATION CONTACT: https://www.hhs.gov/healthit/ahic/ ce_main.html. SUPPLEMENTARY INFORMATION: The meeting will be available via Web cast at https://www.eventcenterlive.com/ cfmx/ec/login/login1.cfm?BID=67. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention Advisory Committee on Immunization Practices In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC) announces the following teleconference. PO 00000 Frm 00082 Fmt 4703 Sfmt 4703 Name: Advisory Committee on Immunization Practices (ACIP). Time and Date: 2 p.m.–4 p.m., May 4, 2006. Place: National Immunization Program (NIP), Atlanta, Georgia. To participate, please call 1–888–769–8923, pass code 3537839. Status: Open to the public, limited only by the availability of telephone ports. Purpose: The committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents. In addition, under 42 U.S.C. 1396s, the committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines. Matters To Be Discussed: Varicella vaccination policy options. This notice is being published less than 15 days as provided under 41 CFR 102–3.150(b), the public health urgency of this agency business requires that the teleconference be held prior to the first available date for publication of this notice in the Federal Register. Contact Person for More Information: Demetria Gardner, Epidemiology and Surveillance Division, National Immunization Program, CDC, 1600 Clifton Road, NE, Mail Stop E–61, Atlanta, Georgia 30333, telephone 404–639–8096, fax 404– 639–8616. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities for both the CDC and the Agency for Toxic Substances and Disease Registry. Dated: April 20, 2006. Alvin Hall, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 06–3987 Filed 4–25–06; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services Privacy Act of 1974; Report of a New System of Records Department of Health and Human Services (HHS), Centers for Medicare & Medicaid Services (CMS). ACTION: Notice of a New System of Records (SOR). AGENCY: SUMMARY: In accordance with the requirements of the Privacy Act of 1974, we are proposing to establish a new system titled, ‘‘Medicare Health Support System (MHS), System No. 09–70– 0574.’’ The program is mandated by E:\FR\FM\26APN1.SGM 26APN1

Agencies

DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 71, Number 80 (Wednesday, April 26, 2006)]
[Notices]
[Pages 24717-24718]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-3918]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES


Office of the National Coordinator; American Health Information 
Community Chronic Care Workgroup Meeting

ACTION: Announcement of meeting.

-----------------------------------------------------------------------

SUMMARY: This notice announces the fifth meeting of the American Health 
Information Community Chronic Care Workgroup in accordance with the 
Federal Advisory Committee Act (Pub. L. 92-463, 5 U.S.C., App.).

DATES: May 3, 2006 from 1 p.m. to 5 p.m.

ADDRESSES: Mary C. Switzer Building (330 C Street, SW., Washington, DC 
20201), Conference Room 4090.

FOR FURTHER INFORMATION CONTACT: https://www.hhs.gov/healthit/ahic/cc_
main.html.

SUPPLEMENTARY INFORMATION: The meeting will be available via Web cast 
at https://www.eventcenterlive.com/cfmx/ec/login/login1.cfm?BID=67.


[[Page 24718]]


    Dated: April 13, 2006.
Kelly Cronin,
Director, Office of Programs and Coordination, Office of the National 
Coordinator.
[FR Doc. 06-3918 Filed 4-25-06; 8:45 am]
BILLING CODE 4150-24-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.